ACRS vs DERM

For growth investors, Journey Medical Corporation (DERM) is the stronger pick with -29.

1% revenue growth year-over-year, versus -58. 2% for Aclaris Therapeutics, Inc. (ACRS). Analysts rate Aclaris Therapeutics, Inc. (ACRS) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Journey Medical Corporation (DERM) delivered a total return of -47.

4%, compared to -78. 8% for Aclaris Therapeutics, Inc. (ACRS). Over 10 years, the gap is even starker: DERM returned -47. 4% versus ACRS's -76. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Aclaris Therapeutics, Inc.

(ACRS) is the lower-risk stock at 0. 30β versus Journey Medical Corporation's 1. 82β — meaning DERM is approximately 499% more volatile than ACRS relative to the S&P 500.

By revenue growth (latest reported year), Journey Medical Corporation (DERM) is pulling ahead at -29.

1% versus -58. 2% for Aclaris Therapeutics, Inc. (ACRS). On earnings-per-share growth, the picture is similar: Aclaris Therapeutics, Inc. grew EPS 69. 0% year-over-year, compared to -242. 9% for Journey Medical Corporation. Over a 3-year CAGR, DERM leads at -3. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Journey Medical Corporation (DERM) is the more profitable company, earning -26.

1% net margin versus -829. 6% for Aclaris Therapeutics, Inc. — meaning it keeps -26. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DERM leads at -24. 4% versus -975. 9% for ACRS. At the gross margin level — before operating expenses — ACRS leads at 73. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for DERM: 135.

0% to $11. 75.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Aclaris Therapeutics, Inc.

(ACRS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 30)). Journey Medical Corporation (DERM) carries a higher beta of 1. 82 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ACRS: -76. 3%, DERM: -47. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.